lavatherapeutics.com (LVTX) Long-Term Debt to Capital Ratio

LAVA Therapeutics NV - graphic logo of issuer LVTX

Risks for LAVA Therapeutics N.V. (LVTX) are linked to global supply chain instability and the complexity of protecting patents abroad. The ratio of long-term debt to equity clearly illustrates the financial leverage, where the metric value stands at 0.00. LAVA Therapeutics N.V. (LVTX) focuses on the Gammabody platform to combat hematological malignancies via T-cells. However, a lack of pricing power forces the business to rely on venture capital investments and payments from pharma partners.

Long-Term Debt to Equity: LAVA Therapeutics NV (LVTX) for 07/04/2022 - 12/06/2025

Analytical breakdowns for LAVA Therapeutics N.V.

- market price and analyst price targets:
Market Price Lava Tx|LVTX - Price Target Chart
- market capitalization details:
Market Capitalization LAVA Therapeutics N.V.|LVTX - Enterprise Value
- issuer book value statistics:
Accounting Value per Share LAVA Therapeutics|LVTX - Company Book Value|Market-to-Book Ratio lavatherapeutics.com|LVTX - Aggregate Company Assets
- debt and solvency information:
Debt to Equity LAVA Therapeutics N.V.|LVTX - Long-Term Debt to Equity|Current Liabilities to Capital Lava Tx|LVTX - Company Aggregate Debts|Debt to Net Assets LAVA Therapeutics N.V.|LVTX - Company Long-Term Liabilities|Short-Term Debt LAVA Therapeutics|Intermediate Coverage Ratio lavatherapeutics.com
- company profitability and valuation multiples indicators:
LVTX - Net Profit
Summary company analysis:LVTX - lavatherapeutics.com
Brand item of LAVA Therapeutics

LAVA Therapeutics N.V. (LVTX) minimizes capital expenditures by outsourcing antibody production and testing to external contractors. An analysis of long-term debt-to-equity allows for an assessment of this strategy's effectiveness through the lens of credit burden. The ratio correlates liabilities with a maturity of over one year against the company's own equity. A decrease in this metric confirms financial stability, whereas excessive leverage may accelerate profit growth. This asset is classified as a high-risk biotechnological security.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Compass Therapeutics|Long-Term Liabilities to Capital replimune.com REPL|Long-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Long-Term Indebtedness to Equity|Pyxis Oncology - Long-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Long-Term Liabilities to Capital|IOBT: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient STRO (sutrobio.com)|INKT: Long-Term Debt to Capital|HOWL - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Immix Biopharma Inc.|Long-Term Debt to Equity Ratio alxoncology.com (ALXO)|Long-Term Debt to Equity Cue Biopharma (CUE)|Long-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital MAIA Biotech MAIA|LIMN - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc